Strides Pharma Science Limited (BOM:532531)
India · Delayed Price · Currency is INR 865.60
-12.00 (-1.37%)
At close: Feb 12, 2026
Strides Pharma Science Income Statement
Financials in millions INR. Fiscal year is April - March.
Millions INR. Fiscal year is Apr - Mar.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Dec '25 Dec 31, 2025 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 | Mar '21 Mar 31, 2021 |
Revenue | 47,256 | 45,653 | 38,901 | 36,884 | 30,703 | 33,159 |
Revenue Growth (YoY) | 3.19% | 17.36% | 5.47% | 20.13% | -7.41% | 20.49% |
Cost of Revenue | 20,700 | 21,285 | 19,109 | 17,580 | 16,136 | 14,214 |
Gross Profit | 26,556 | 24,369 | 19,793 | 19,304 | 14,566 | 18,945 |
Selling, General & Admin | 9,747 | 9,328 | 7,893 | 7,686 | 6,728 | 5,704 |
Other Operating Expenses | 7,787 | 7,025 | 6,154 | 7,746 | 7,881 | 6,896 |
Operating Expenses | 19,515 | 18,276 | 16,184 | 17,864 | 16,939 | 14,662 |
Operating Income | 7,042 | 6,093 | 3,609 | 1,439 | -2,373 | 4,282 |
Interest Expense | -1,459 | -2,074 | -2,385 | -2,176 | -1,457 | -1,244 |
Interest & Investment Income | 479.95 | 479.95 | 304.29 | 745.28 | 1,076 | 364.94 |
Earnings From Equity Investments | 21.47 | 18.37 | -539.67 | -2,853 | -1,108 | -978.19 |
Currency Exchange Gain (Loss) | 33.5 | 33.5 | 96.41 | 448.88 | -97.84 | 80.17 |
Other Non Operating Income (Expenses) | 589.53 | -368.89 | -357.45 | -345.98 | -239.31 | -215.14 |
EBT Excluding Unusual Items | 6,708 | 4,182 | 727.45 | -2,741 | -4,199 | 2,290 |
Merger & Restructuring Charges | -967.92 | 49.54 | -30.8 | 469.56 | -2,145 | -23.61 |
Gain (Loss) on Sale of Investments | - | - | - | - | 0.04 | - |
Gain (Loss) on Sale of Assets | 40.95 | 40.95 | 14.32 | 41.07 | 112.47 | 23.38 |
Asset Writedown | 0.01 | -0.05 | -1,575 | -330.4 | -46.76 | - |
Other Unusual Items | 489.38 | 597.12 | -283.83 | -301.08 | -246.06 | 464.59 |
Pretax Income | 6,270 | 4,869 | -1,148 | -2,862 | -6,525 | 2,754 |
Income Tax Expense | 961.55 | 775.16 | 291.12 | -553.01 | -1,783 | 316.51 |
Earnings From Continuing Operations | 5,309 | 4,094 | -1,439 | -2,309 | -4,743 | 2,438 |
Earnings From Discontinued Operations | - | 31,881 | 495.92 | 185.69 | - | 139.41 |
Net Income to Company | 5,309 | 35,975 | -943.12 | -2,123 | -4,743 | 2,577 |
Minority Interest in Earnings | -194.14 | -40.57 | 237 | 96.95 | 140.39 | 107.13 |
Net Income | 5,114 | 35,935 | -706.12 | -2,026 | -4,602 | 2,684 |
Net Income to Common | 5,114 | 35,935 | -706.12 | -2,026 | -4,602 | 2,684 |
Net Income Growth | -85.51% | - | - | - | - | 637.66% |
Shares Outstanding (Basic) | 92 | 92 | 91 | 90 | 90 | 90 |
Shares Outstanding (Diluted) | 92 | 92 | 91 | 90 | 90 | 90 |
Shares Change (YoY) | 0.23% | 1.12% | 1.02% | 0.37% | 0.04% | 0.14% |
EPS (Basic) | 55.49 | 390.55 | -7.76 | -22.49 | -51.28 | 29.96 |
EPS (Diluted) | 55.49 | 390.50 | -7.76 | -22.50 | -51.28 | 29.92 |
EPS Growth | -85.54% | - | - | - | - | 637.04% |
Free Cash Flow | - | 4,419 | 5,829 | -505.27 | -4,012 | 1,840 |
Free Cash Flow Per Share | - | 48.02 | 64.06 | -5.61 | -44.70 | 20.50 |
Dividend Per Share | - | 4.000 | 2.500 | 1.500 | - | 2.500 |
Dividend Growth | - | 60.00% | 66.67% | - | - | 25.00% |
Gross Margin | 56.20% | 53.38% | 50.88% | 52.34% | 47.44% | 57.13% |
Operating Margin | 14.90% | 13.35% | 9.28% | 3.90% | -7.73% | 12.91% |
Profit Margin | 10.82% | 78.71% | -1.81% | -5.49% | -14.99% | 8.10% |
Free Cash Flow Margin | - | 9.68% | 14.98% | -1.37% | -13.07% | 5.55% |
EBITDA | 8,513 | 7,688 | 5,371 | 3,403 | -494.5 | 5,942 |
EBITDA Margin | 18.01% | 16.84% | 13.81% | 9.23% | -1.61% | 17.92% |
D&A For EBITDA | 1,471 | 1,595 | 1,762 | 1,964 | 1,879 | 1,660 |
EBIT | 7,042 | 6,093 | 3,609 | 1,439 | -2,373 | 4,282 |
EBIT Margin | 14.90% | 13.35% | 9.28% | 3.90% | -7.73% | 12.91% |
Effective Tax Rate | 15.33% | 15.92% | - | - | - | 11.49% |
Revenue as Reported | 48,802 | 46,241 | 39,298 | 37,787 | 32,022 | 33,673 |
Advertising Expenses | - | 544.02 | 365.07 | 221.73 | 178.18 | 130.48 |
Updated Dec 31, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.